Commit Biologics launches with €16m seed financing to pioneer complement system activation to treat cancer and autoimmune disease

  • Financing led by Bioqube Ventures and Novo Holdings
  • Commit is pioneering a novel approach to activating the complement component of the immune system to treat cancer and autoimmune diseases
  • Its unique bispecific technology (BiCE™) engages the complement system, unleashing its power to selectively kill target cells
  • Spin-out from Aarhus University in Denmark, a world leader in complement structural biology

Aarhus, Denmark – 9 May 2024 – Commit Biologics (“Commit”), a pioneer in the activation of the complement system to treat cancer and autoimmune disease, today exits from stealth with €16m in seed funding from Bioqube Ventures and Novo Holdings.

Read more…